XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
On June 15, 2026, FDA issued Warning Letter 320-26-95 to Huons Co., Ltd., a drug manufacturing facility located at 100 Bio Valley-ro, Jecheon, Chungcheongbuk, South Korea, citing systemic data integrity violations following an inspection
View details →
On June 2, 2026, FDA issued Warning Letter 320-26-89 to Revlon Group Holdings, LLC at its Oxford, North Carolina facility — a registered OTC drug product manufacturer — citing significant violations of Current Good
View details →
Production and process controls 483 observations are the category where FDA's regulatory findings intersect most directly with your CMC submission — because the process controls FDA finds inadequate in your facility are almost always
View details →
Of all the ALCOA+ principles, contemporaneous documentation is the one that generates the most Warning Letters — not because companies are falsifying records, but because decades of informal documentation practices have normalized the idea
View details →
On June 25, 2026, FDA issued Warning Letter 320-26-98 to Excelvision (a Fareva facility) in Annonay, France, following an inspection conducted January 12 to 22, 2026 — the second warning letter this site has
View details →
On June 24, 2026, FDA issued Warning Letter 320-26-97 to Wizcure Pharmaa Private Limited in Bhiwadi, Rajasthan, India, following an inspection conducted December 3 to 10, 2025 — a ten-day inspection that documented one
View details →
Container-closure suitability and product-contact-material risk are long-standing CMC expectations. The current architecture should distinguish binding requirements and final guidance from evolving scientific frameworks: USP <1663>/<1664> provide extractables/leachables assessment frameworks; industry consortia such as BPOG
View details →
The shared laboratory login is one of the most common data integrity violations FDA finds during inspections — and it is also one of the most dangerous, because a shared login means that no
View details →
"The proposed shelf life of 24 months is not supported by the data provided." Three years after ICH Q1E has been in effect, this deficiency continues to appear in CMC letters because the difference
View details →
FDA investigators closed an 11-day inspection of Catalent Indiana LLC's sterile injectable facility in Bloomington, Indiana, on April 24, 2026, documenting eight inspectional observations spanning environmental monitoring, aseptic process validation, visual inspection, and investigation
View details →
The Quality Overall Summary is the first CMC document a regulatory reviewer reads. It sets their expectations, frames the complexity of the submission, and either reassures them that the applicant understands their own data
View details →
FDA investigators are trained to look for what is missing from your data records before they look at what is present — and the deletion of failed runs, rejected results, or inconvenient data points
View details →
"When a regulatory reviewer opens the QOS drug product section, they are looking for three things: that you understand why your formulation is designed the way it is, that your analytical methods are capable
View details →
Most pharmaceutical companies operating in both the US and EU believe that if their electronic systems comply with 21 CFR Part 11, they also satisfy EU Annex 11 — this assumption is the source
View details →
The average NDA CMC review cycle includes at least one round of deficiencies. The average ANDA review includes two. The companies that convert deficiency letters into expedited approvals are not those with the fewest
View details →
An audit trail that exists but is never reviewed is not a compliance control — it is a liability waiting to be discovered by an FDA investigator who will review it more thoroughly in
View details →
The approval of a new drug application is not the end of CMC regulatory work — it is the beginning of a decades-long change management challenge. The most expensive regulatory decisions in pharmaceutical product
View details →
The most dangerous statement in pharmaceutical quality is "the result was retested and passed" — because that sentence, without the three-phase investigation framework that FDA requires before any retest is scientifically valid, is the
View details →